SARS-CoV-2: At the Crossroad Between Aging and Neurodegeneration
Alice Lippi MSc
Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany
Center of Excellence for Science and Technology-Integration of Mediterranean Region (STIM), Faculty of Science, University of Split, Split, Croatia
Search for more papers by this authorRenato Domingues MSc
Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany
Search for more papers by this authorCristian Setz MD
Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany
Department of Otolaryngology-Head and Neck Surgery, University Medical Center Goettingen, Goettingen, Germany
Search for more papers by this authorCorresponding Author
Tiago F. Outeiro PhD
Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany
Max Planck Institute for Experimental Medicine, Goettingen, Germany
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Framlington Place, Newcastle Upon Tyne, United Kingdom
Correspondence to: Dr. Anita Krisko, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]; or Prof. Dr. Tiago F. Outeiro, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]Search for more papers by this authorCorresponding Author
Anita Krisko PhD
Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany
Correspondence to: Dr. Anita Krisko, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]; or Prof. Dr. Tiago F. Outeiro, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]Search for more papers by this authorAlice Lippi MSc
Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany
Center of Excellence for Science and Technology-Integration of Mediterranean Region (STIM), Faculty of Science, University of Split, Split, Croatia
Search for more papers by this authorRenato Domingues MSc
Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany
Search for more papers by this authorCristian Setz MD
Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany
Department of Otolaryngology-Head and Neck Surgery, University Medical Center Goettingen, Goettingen, Germany
Search for more papers by this authorCorresponding Author
Tiago F. Outeiro PhD
Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany
Max Planck Institute for Experimental Medicine, Goettingen, Germany
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Framlington Place, Newcastle Upon Tyne, United Kingdom
Correspondence to: Dr. Anita Krisko, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]; or Prof. Dr. Tiago F. Outeiro, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]Search for more papers by this authorCorresponding Author
Anita Krisko PhD
Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany
Correspondence to: Dr. Anita Krisko, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]; or Prof. Dr. Tiago F. Outeiro, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]Search for more papers by this author
References
- 1Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579: 265–269.
- 2Chen X, Yu B. First two months of the 2019 Coronavirus Disease (COVID-19) epidemic in China: real-time surveillance and evaluation with a second derivative model. Glob Health Res Policy 2020; 5: 7.
- 3Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1967–1976.
- 4Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367: 1814–1820.
- 5Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med 2020; 382: 1199–207.
- 6Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic human coronaviruses. Adv Virus Res 2018; 100: 163–188.
- 7Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016; 24: 490–502.
- 8de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016; 14: 523–534.
- 9Menachery VD, Eisfeld AJ, Schäfer A, et al. Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses. mBio 2014; 5: e01174-14.
- 10Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. biorxiv 2020.03.22.002386v1. [Preprint].
- 11Reineke LC, Lloyd RE. The stress granule protein G3BP1 recruits protein kinase R to promote multiple innate immune antiviral responses. J Virol 2015; 89: 2575–2589.
- 12Yang W, Ru Y, Ren J, et al. G3BP1 inhibits RNA virus replication by positively regulating RIG-I-mediated cellular antiviral response. Cell Death Dis 2019; 10: 946.
- 13Kim SSY, Sze L, Lam KP. The stress granule protein G3BP1 binds viral dsRNA and RIG-I to enhance interferon-β response. J Biol Chem 2019; 294: 6430–6438.
- 14Raaben M, Groot Koerkamp MJA, Rottier PJM, de Haan CAM. Mouse hepatitis coronavirus replication induces host translational shutoff and mRNA decay, with concomitant formation of stress granules and processing bodies. Cell Microbiol 2007; 9: 2218–2229.
- 15López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013; 153: 1194–1217.
- 16Cao M, Wei C, Zhao L, et al. DnaJA1/Hsp40 is co-opted by influenza a virus to enhance its viral RNA polymerase activity. J Virol 2014; 88: 14078–14089.
- 17Sharma K, Tripathi S, Ranjan P, et al. Influenza A virus nucleoprotein exploits Hsp40 to inhibit PKR activation. PLoS One 2011; 6:e20215.
- 18Batra J, Tripathi S, Kumar A, et al. Human heat shock protein 40 (Hsp40/DnaJB1) promotes influenza A virus replication by assisting nuclear import of viral ribonucleoproteins. Sci Rep 2016; 6: 19063.
- 19Hirayama E, Atagi H, Hiraki A, Kim J. Heat shock protein 70 is related to thermal inhibition of nuclear export of the influenza virus ribonucleoprotein complex. J Virol. 2004; 78: 1263–70.
- 20Manzoor R, Kuroda K, Yoshida R, Tsuda Y, Fujikura D, Miyamoto H, et al. Heat shock protein 70 modulates influenza A virus polymerase activity. J Biol Chem. 2014; 289: 7599–614.
- 21Momose F, Naito T, Yano K, Sugimoto S, Morikawa Y, Nagata K. Identification of Hsp90 as a stimulatory host factor involved in influenza virus RNA synthesis. J Biol Chem 2002; 277: 45306–45314.
- 22Naito T, Momose F, Kawaguchi A, Nagata K. Involvement of Hsp90 in assembly and nuclear import of influenza virus RNA polymerase subunits. J Virol 2007; 81: 1339–1349.
- 23Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000; 2: 469–475.
- 24Pandey P. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J 2000; 19: 4310–4322.
- 25Chan CP, Siu KL, Chin KT, Yuen KY, Zheng B, Jin DY. Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein. J Virol 2006; 80: 9279–9287.
- 26Levine B. Eating oneself and uninvited guests. Cell 2005; 120: 159–162.
- 27Marreiros R, Müller-Schiffmann A, Trossbach SV, et al. Disruption of cellular proteostasis by H1N1 influenza A virus causes α-synuclein aggregation. Proc Natl Acad Sci U S A 2020; 117: 6741–6751.
- 28Cottam EM, Whelband MC, Wileman T. Coronavirus NSP6 restricts autophagosome expansion. Autophagy 2014; 10: 1426–1441.
- 29Shi CS, Qi HY, Boularan C, et al. SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome. J Immunol 2014; 193: 3080–3089.
- 30Gack MU, Albrecht RA, Urano T, et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 2009; 5: 439–449.
- 31Widjaja I, de Vries E, Tscherne DM, Garcia-Sastre A, Rottier PJM, de Haan CAM. Inhibition of the ubiquitin-proteasome system affects influenza A virus infection at a postfusion step. J Virol 2010; 84: 9625–9631.
- 32Liu XD, Ko S, Xu Y, et al. Transient aggregation of ubiquitinated proteins is a cytosolic unfolded protein response to inflammation and endoplasmic reticulum stress. J Biol Chem 2012; 287: 19687–19698.
- 33Ye Z, Wong CK, Li P, Xie Y. A SARS-CoV protein, ORF-6, induces caspase-3 mediated, ER stress and JNK-dependent apoptosis. Biochim Biophys Acta 2008;1780: 1383–1387.
- 34Li S, Min JY, Krug RM, Sen GC. Binding of the influenza A virus NS1 protein to PKR mediates the inhibition of its activation by either PACT or double-stranded RNA. Virology 2006; 349: 13–21.
- 35Grelak RP, Clark R, Stump JM, Vernier VG. Amantadine-dopamine interaction: possible mode of action in Parkinsonism. Science 1970; 169: 203–204.
- 36Bauer RB, McHenry JT. Comparison of amantadine, placebo, and levodopa in Parkinson's disease. Neurology 1974; 24: 715–720.
- 37Danielczyk W. Twenty-five years of amantadine therapy in Parkinson's disease. J Neural Transm Suppl 1995; 46: 399–405.
- 38Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307: 580–584.
- 39Blake GJ. Amantadine for influenza A. Nursing 1990; 20: 21.
- 40Kadowaki T, Komagamine T, Suzuki K, Hirata K. Oseltamivir-induced dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2011; 17: 133–134.
- 41Toovey S, Jick SS, Meier CR. Parkinson's disease or Parkinson symptoms following seasonal influenza: influenza and Parkinson's disease. Influenza Other Respir Viruses 2011; 5: 328–333.
- 42Allen Reish HE, Standaert DG. Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis 2015; 5: 1–19.
- 43Roodveldt C, Labrador-Garrido A, Izquierdo G, Pozo D. Alpha-synuclein and the immune response in Parkinson's disease. In: Finkelstein D, ed. Towards New Therapies for Parkinson's Disease [Internet]. InTech; 2011 [cited 2020 Apr 3]. Available from: http://www.intechopen.com/books/towards-new-therapies-for-parkinson-s-disease/alpha-synuclein-and-the-immune-response-in-parkinson-s-disease. .
- 44Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease. Mov Disord 1992; 7: 153–158.
- 45Yamada T. Viral etiology of Parkinson's disease: focus on influenza A virus. Parkinsonism Relat Disord 1996; 2: 113–121.
- 46Beatman EL, Massey A, Shives KD, et al. Alpha-synuclein expression restricts RNA viral infections in the brain. J Virol 2016; 90: 2767–2782.
- 47Shutinoski B, Hakimi M, Harmsen IE, et al. Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner. Sci Transl Med 2019;11:eaas9292.
- 48Hakimi M, Selvanantham T, Swinton E, et al. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 2011; 118: 795–808.
Citing Literature
